Goldman Sachs Group Inc. Has $406,000 Position in CeriBell, Inc. $CBLL

Key Points

• Goldman Sachs Group Inc. has reduced its stake in CeriBell, Inc. by 67.5%, now owning only 21,137 shares worth approximately $406,000.
• CeriBell reported earnings exceeding analysts' expectations with a revenue of $21.20 million for the quarter, while its earnings per share were at ($0.38).
• The stock has an average analyst rating of "Buy" with a consensus price target of $32.14, despite a recent trading price around $11.37.

Goldman Sachs Group Inc. cut its holdings in shares of CeriBell, Inc. (NASDAQ:CBLL - Free Report) by 67.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,137 shares of the company's stock after selling 43,865 shares during the quarter. Goldman Sachs Group Inc. owned about 0.06% of CeriBell worth $406,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. TimesSquare Capital Management LLC acquired a new stake in shares of CeriBell during the 1st quarter worth about $10,312,000. Federated Hermes Inc. raised its holdings in CeriBell by 111.3% in the 1st quarter. Federated Hermes Inc. now owns 786,751 shares of the company's stock valued at $15,113,000 after acquiring an additional 414,500 shares during the period. CenterBook Partners LP bought a new position in CeriBell in the 1st quarter valued at about $3,531,000. Swiss National Bank bought a new position in CeriBell in the 1st quarter valued at about $467,000. Finally, Lord Abbett & CO. LLC grew its position in shares of CeriBell by 7.9% in the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after purchasing an additional 23,451 shares during the last quarter.

CeriBell Price Performance

NASDAQ:CBLL opened at $11.37 on Friday. The firm's 50-day simple moving average is $12.66 and its 200 day simple moving average is $15.84. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The firm has a market cap of $416.82 million and a price-to-earnings ratio of -3.80. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The firm had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.52 million. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Insiders Place Their Bets

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total value of $442,500.00. Following the completion of the transaction, the chief executive officer directly owned 776,022 shares of the company's stock, valued at $13,735,589.40. The trade was a 3.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, BTIG Research assumed coverage on CeriBell in a research report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, CeriBell has an average rating of "Buy" and a consensus price target of $32.14.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.